Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 23;14(7):1632.
doi: 10.3390/cancers14071632.

Biopsy Ratio of Suspected to Confirmed Sarcoma Diagnosis

Nasian Mosku  1   2 , Philip Heesen  2 , Gabriela Studer  1   2 , Beata Bode  2 , Vito Spataro  2 , Natalie D Klass  2 , Lars Kern  2 , Mario F Scaglioni  1   2 , Bruno Fuchs  1   2
Affiliations

Biopsy Ratio of Suspected to Confirmed Sarcoma Diagnosis

Nasian Mosku et al. Cancers (Basel). .

Abstract

The ratio of malignancy in suspicious soft tissue and bone neoplasms (RMST) has not been often addressed in the literature. However, this value is important to understand whether biopsies are performed too often, or not often enough, and may therefore serve as a quality indicator of work-up for a multidisciplinary team (MDT). A prerequisite for the RMST of an MDT is the assessment of absolute real-world data to avoid bias and to allow comparison among other MDTs. Analyzing 950 consecutive biopsies for sarcoma-suspected lesions over a 3.2-year period, 55% sarcomas were confirmed; 28% turned out to be benign mesenchymal tumors, and 17% non-mesenchymal tumors, respectively. Of these, 3.5% were metastases from other solid malignancies, 1.5% hematologic tumors and 13% sarcoma simulators, which most often were degenerative or inflammatory processes. The RMST for biopsied lipomatous lesions was 39%. The ratio of unplanned resections was 10% in this series. Reorganizing sarcoma work-up into integrating practice units (IPU) allows the assessment of real-world data with absolute values over the geography, thereby enabling the definition of quality indicators and addressing cost efficiency aspects of sarcoma care.

Keywords: biopsy; confirmation; ratio; sarcoma; suspicion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Types of lesions after biopsy.
Figure 2
Figure 2
List of benign mesenchymal tumors.
Figure 3
Figure 3
Histological types of sarcoma diagnoses.
Figure 4
Figure 4
Types of lesions other than mesenchymal tumors.
See this image and copyright information in PMC

References

    1. Ng V.Y., Scharschmidt T.J., Mayerson J.L., Fisher J.L. Incidence and survival in sarcoma in the United States: A focus on musculoskeletal lesions. Anticancer Res. 2013;33:2597–2604. - PubMed
    1. Lins L., Carvalho F.M. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4:2050312116671725. doi: 10.1177/2050312116671725. - DOI - PMC - PubMed
    1. Qi D., Zhao M., Hu T., Zhang G. Diagnostic yield of percutaneous core needle biopsy in suspected soft tissue lesions of extremities. J. Int. Med. Res. 2019;47:2598–2606. doi: 10.1177/0300060519849294. - DOI - PMC - PubMed
    1. Traina F., Errani C., Toscano A., Pungetti C., Fabbri D., Mazzotti A., Donati D., Faldini C. Current concepts in the biopsy of musculoskeletal tumors. J. Bone. Jt. Surg. Am. 2015;97:e7. doi: 10.2106/JBJS.N.00661. - DOI - PubMed
    1. Didolkar M.M., Anderson M.E., Hochman M.G., Rissmiller J.G., Goldsmith J.D., Gebhardt M.G., Wu J.S. Image Guided Core Needle Biopsy of Musculoskeletal Lesions: Are Nondiagnostic Results Clinically Useful? Clin. Orthop. Relat. Res. 2013;471:3601–3609. doi: 10.1007/s11999-013-3170-9. - DOI - PMC - PubMed

LinkOut - more resources